InflaRx $IFRX
PG P3 update Q2 vilobelimab
INF904 data Q2 HS / CSU
Last week EMA approved #Gohibic 1st ever for #ARDS 
FDA approved drug, (1) P3 (3) P2, #BARDA funded ongoing study. $150m mkt cap; $80m cash through 2026.  Could be 10-50x if stars align or 5-10x if 1 star aligns.